![[Bio USA] SK Biopharmaceuticals teams up with PhnyX Lab to boost AI-based drug development](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F18%2Fnews-p.v1.20250618.7cc012dccaa842089c2e1b76d1e0c1b6_T1.jpg&w=3840&q=100)
[Bio USA] SK Biopharmaceuticals teams up with PhnyX Lab to boost AI-based drug development
BOSTON -- SK Biopharmaceuticals announced Tuesday that it had signed a mutual strategic business agreement with AI startup PhnyX Lab during the Bio USA 2025 convention held in Boston, aiming to establish an AI-powered drug development framework.
Through the agreement, the two companies will co-develop a customized solution that automates key processes in drug development such as literature searches, data analysis and document generation, using PhnyX Lab's proprietary generative AI platform Cheiron.
The collaboration will especially focus on automating regulatory documentation required for clinical trial initiation, expediting what SK Biopharmaceuticals calls a "full-scale AI transformation" of its drug development workflow. The company expects this shift to significantly enhance R&D productivity while dramatically reducing the time and cost associated with drug development and approval.
"Pharmaceutical and biotech industries face significant challenges in digital transformation due to their complex workflows and heavy regulation," said Bae Min-seok, CEO of PhnyX Lab. 'The partnership demonstrates that generative AI solutions can be effectively applied in real-world settings to improve both efficiency and accuracy in pharmaceutical operations.'
As Cheiron is an end-to-end AI solution tailored for the pharmaceutical and biotech sector, the system also connects with official databases from regulatory bodies such as the US FDA and Korea's Ministry of Food and Drug Safety, as well as the Medical Subject Headings (MeSH) classification system, to deliver high accuracy and practical utility.
'AI is no longer a choice, but a core capability in drug development,' said Lee Dong-hoon, CEO of SK Biopharmaceuticals. 'By partnering with PhnyX Lab, we plan to further embed AI into every stage of our drug development process and strengthen our competitiveness in the global market.'
SK Biopharmaceuticals has already been utilizing its in-house AI platform Huble in the early stages of drug development, particularly in analyzing disease-causing genes and proteins and identifying drug candidates. Through the new collaboration, the company plans to expand the application of AI across its operations to maximize productivity.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
18 hours ago
- Korea Herald
Woori Financial takes cue from aging Japan
A think tank under South Korea's financial service provider Woori Financial Group published a book Wednesday exploring how Japan adapted to aging demographics, redefined its financial and corporate landscape and what lessons Korea can draw from the transformation. Titled The Great Shift in Japan's Economy (tentative translation), the book is the result of a yearlong research project conducted by the Woori Finance Research Institute, which included in-person interviews and case studies, looking into the country's corporate culture reforms, digital innovations and changed role of financial institutions. "While initiatives such as the shareholder return policy were effective, the success of the Japanese financial institutions' value-up strategy was mainly driven by their global business," Woori Finance Research Institute CEO Park Jung-hoon said at a press conference held at the bank's headquarters in central Seoul, Wednesday. In the book, the think tank delved into the global expansion of Japan's three major financial firms, Mitsubishi UFJ Financial Group, Sumitomo Mitsui Financial Group, and Mizuho Financial Group. Struggling with the Japanese central bank's prolonged monetary easing, the three firms altered in their business targets, setting their sights on global operations. As a result, their overseas operating profits surged fivefold between 2006 and 2023. Earnings from overseas operations took up roughly 50 percent of the total operating profits for the firms in 2023,more than three times what they did in 2006 — 15 percent. "It took over 10 years for the Japanese finance firms to bear fruit in their global operations. Korean financial companies have to continuously strengthen their global competitiveness in a long-term perspective,' Park said. Taking a hint from Japan and its aging society, Woori Financial plans to bolster its senior-targeted operations, too. Having gained the green light from the authorities to acquire Tongyang Life and ABL Life, the finance group is to officially incorporate the insurers into its portfolio in July. "With the acquisition of the insurers, Woori Financial is looking into how the group can offer senior-targeted financial services. We are studying Japanese cases through business trips, visiting nursing homes, and meeting experts. Woori Finance Research Institute will continue to study how the group can encompass seniors in its business, as it is a meaningful agenda on a national level,' Park said.
Korea Herald
18 hours ago
- Korea Herald
Seoul mayor meets with veterans, vows support expansion
To mark Patriots and Veterans Month in June, the Seoul Metropolitan Government held a roundtable Wednesday with veterans' group representatives, presenting updates on the city's major commemorative infrastructure projects and welfare policies for those who served. Wednesday's meeting, held at Seoul City Hall, brought together Seoul Mayor Oh Se-hoon and 15 representatives from major veterans groups based in the city, including Ryu Jae-sik of the Korean War Veterans Association, Kim Bu-gil of the Vietnam Veterans Association Korea and Kim Dae-ha of the Heritage of Korean Independence. During Wednesday's meeting, Oh shared the city's vision for building a second Veterans Hall in Yongsan-gu, central Seoul, complementing the existing facility in Mapo-gu, western Seoul. According to a city government official, the existing facility in western Seoul has reached full capacity and can only accommodate four of the city's 15 veterans' organizations. The new hall is scheduled to be built by 2030 and will include not just offices for veterans' groups but also exhibition halls and educational facilities for veterans' organizations to use. The Seoul Mayor also presented updates on the Garden of Gratitude, a symbolic space dedicated to honoring the veterans and countries that participated in the 1950-53 Korean War. Set to be constructed at Gwanghwamun Square by 2027 to honor Korean veterans and the 22 countries that supported South Korea during the Korean War, Oh added that the city government aims to remember the sacrifices of veterans who 'laid the foundation for South Korea's prosperity' and 'create a space that conveys gratitude for their contributions.' 'This space will serve as a place where visitors and passersby can remember and reflect on the value veterans hold in our everyday lives,' said Oh. The Seoul Metropolitan Government currently supports over 100,000 veterans and their families. This year, the city government has allocated more than 100 billion won ($72.9 million) to bolster veterans' welfare services. Among key programs receiving increased funding is the city's Honorary Funeral Service for veterans, which provides ceremonial support at the request of bereaved families, including escorts, the presentation of the national flag and condolence visits. Previously, the program's reach was limited to around 40 percent of applicants due to budget and personnel constraints, but the city government plans to raise this coverage rate to 80 percent through its supplementary budget. The city government also announced Wednesday that it will expand its financial assistance to veterans and their families. Starting this year, the monthly subsidy given to individuals who were a part of the April 19 Revolution and veterans who were injured after taking part in wars was raised from 100,000 won to 150,000 won. The subsidy given to veterans aged 80 or older also increased from 150,000 won to 200,000 won. As part of its commemorative efforts, Oh also added that the city will distribute one-time condolence payments in June. Subsidies of up to 100,000 won will be given to families with more than two veterans who died from the war and veterans with severe disabilities, and subsidies of 50,000 won will be given to veterans aged over 80 as well as those part of low-income groups and the spouses of injured or fallen soldiers. The city government will also provide institutional support of up to 3 million won to the Veterans Health Service Medical Center and 300,000 won to each veteran's group branch across Seoul. 'This year marks the 80th anniversary of Korea's liberation and the 75th anniversary of the Korean War,' said Oh. 'Many who are present (in the roundtable meeting) today are the very people who safeguarded Korea in times of crisis. Seoul will continue to honor their sacrifices through policies and commemorative spaces that ensure their heroism is remembered and respected in their everyday lives.'
![[Bio USA] GI Innovation unveils next-gen immunotherapy pipeline](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F18%2Fnews-p.v1.20250618.d08a9f94aea74f3da95329681a945806_T1.jpg&w=3840&q=100)
Korea Herald
20 hours ago
- Korea Herald
[Bio USA] GI Innovation unveils next-gen immunotherapy pipeline
BOSTON -- Korean biotech company GI Innovation showcased its next-generation growth strategy at Bio USA 2025 in Boston on Tuesday. Leading the presentation was Yun Nari, head of GI Innovation's clinical strategy, who introduced the company's new drug development pipeline and global business roadmap. A licensed pharmacist, Yun joined the company's board of directors in March and is expected to play a pivotal role in accelerating clinical decision-making, an essential function in GI Innovation's core business of clinical-stage drug development. A key highlight was the unveiling of GI-128, a novel immuno-oncology candidate that leverages macrophage engagement, an emerging target in next-generation cancer therapies. The company also spotlighted its trispecific antibody pipeline, designed to surpass the current generation of aPD-(L)1/VEGF bispecific antibodies, which are gaining significant traction in the global oncology space. 'This year's Bio USA is a premier platform that brings together leading global investors and pharmaceutical companies,' said Jang Myoung-ho, CEO and founder of GI Innovation. 'It presented the perfect opportunity to demonstrate the competitiveness of our pipeline and global expansion strategy. We plan to actively explore a variety of partnership opportunities, including technology licensing, co-development deals and strategic investments.' Meanwhile, the growing interest in aPD-(L)1/VEGF bispecific antibodies in the immuno-oncology sector has led to a surge in high-value deals. Bristol Myers Squibb recently entered into a licensing agreement with German biotech firm BioNTech, paying an upfront sum of approximately $1.5 billion, with the total deal valued at around $11.1 billion. Likewise, Merck & Co. signed a deal last year with China-based LaNova Medicines, worth $588 million upfront and up to $2.7 billion in milestone payments. Building on this trend, GI Innovation's trispecific antibody platform integrates the company's proprietary aPD-L1 antibody, a VEGF antibody and a macrophage engager into a single molecule. The design aims to overcome the therapeutic limitations of bispecific antibodies by stimulating a more robust immune response within the tumor microenvironment, the company explained.
